Next-Generation Antibody Therapeutics Market Research Report Information By Type of Novel Antibody (Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates), By Target Indication (Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma), By Type of Therapy (Combination Therapy and Monotherapy), By Route of Administration (Intratumoral, Intravenous and Intravesical) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Mar

Global Next-Generation Antibody Therapeutics Market Overview

Next-Generation Antibody Therapeutics Market Size was valued at USD 2.6 Billion in 2022. The Next-Generation Antibody Therapeutics market industry is projected to grow from USD 3.6 Billion in 2023 to USD 43.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 36.60% during the forecast period (2024 - 2032). Increased investment in research and development is one of the key market drivers that enhance market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Next-Generation Antibody Therapeutics Market Trends

• Growing demand for targeted therapies is driving the market growth

Market CAGR for next-generation antibody therapeutics is being driven by the growing demand for targeted therapies. Traditional treatments often lack specificity and can cause significant side effects. In contrast, next-generation antibody therapeutics, such as antibody-drug conjugates (ADCs), bispecific antibodies, and engineered antibodies, offer targeted approaches by selectively binding to specific antigens or cell types involved in disease processes. These targeted therapies offer several advantages, including improved efficacy, reduced toxicity, and enhanced patient outcomes. As a result, there is increasing interest and adoption of next-generation antibody therapeutics across various therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. Pharmaceutical companies are investing in research and development to advance these innovative therapies, driven by the promise of addressing unmet medical needs and providing more effective and personalized treatment options for patients.

Increasing investment in research and development (R&D) is a key driver fueling the growth of the Next-Generation Antibody Therapeutics Market. Biopharmaceutical companies are allocating significant resources to R&D efforts aimed at advancing antibody engineering technologies and developing novel therapeutic modalities. These investments support the discovery and development of next-generation antibody therapeutics, including antibody-drug conjugates (ADCs), bispecific antibodies, and engineered antibodies, with enhanced properties and improved therapeutic potential. Advancements in antibody engineering, drug conjugation technologies, and targeted delivery systems are expanding the scope of possibilities for next-generation antibody therapeutics, driving innovation in the field. Moreover, strategic collaborations between industry players, academic institutions, and research organizations further accelerate R&D efforts and facilitate access to cutting-edge technologies and expertise. Overall, increasing investment in R&D is driving the development of innovative next-generation antibody therapeutics, addressing unmet medical needs and driving growth in the market.

The increasing incidence of chronic diseases, such as cancer, autoimmune disorders, and infectious diseases, is a significant driver propelling the Next-Generation Antibody Therapeutics Market. These conditions pose substantial healthcare burdens globally, necessitating effective and targeted treatment options. Next-generation antibody therapeutics, including antibody-drug conjugates (ADCs), bispecific antibodies, and engineered antibodies, offer promising solutions for addressing the complexities of chronic diseases. By selectively targeting disease-specific antigens or cells, these therapies minimize off-target effects and enhance treatment efficacy. As the prevalence of chronic diseases continues to rise, there is a growing demand for innovative therapeutic approaches that can improve patient outcomes and quality of life. Next-generation antibody therapeutics are well-positioned to meet this demand, driving their adoption and growth in the healthcare market. Thus, driving the Next-Generation Antibody Therapeutics market revenue.

For instance, the Byondis obtained acceptance of its biologics license application from the U.S. FDA for Vic-Trastuzumab Duocarmazine (SYD985), an antibody-drug conjugate, for the treatment of patients diagnosed with HER2-positive advanced breast cancer.

Next-Generation Antibody Therapeutics Market Segment Insights

Next-Generation Antibody Therapeutics Type of Novel Antibody Insights

The Next-Generation Antibody Therapeutics Market segmentation, based on Type of Novel Antibody, includes Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates. In 2023, the immunocytokines segment dominated the market, accounting for 35% of market revenue (1.2 Billion). Immunocytokines, a type of novel antibody, have secured the largest market share in the Next-Generation Antibody Therapeutics Market due to their unique ability to combine the targeting specificity of antibodies with the potent immunomodulatory effects of cytokines. These innovative molecules offer precise targeting of tumor cells while simultaneously stimulating the immune system to enhance anti-tumor immune responses. This dual mechanism of action enhances efficacy and reduces systemic toxicity, making immunocytokines highly attractive for the treatment of various cancers, thereby driving their dominance in the market.

Immunotoxins, a type of novel antibody, are experiencing the highest compound annual growth rate (CAGR) in the Next-Generation Antibody Therapeutics Market due to their unique mechanism of action and promising therapeutic potential. These molecules combine the tumor-targeting specificity of antibodies with the cytotoxic properties of toxins, resulting in highly potent and selective anticancer agents. Immunotoxins offer advantages such as precise tumor targeting, reduced systemic toxicity, and the ability to overcome resistance mechanisms, driving their rapid adoption and growth in the market.

Next-Generation Antibody Therapeutics Target Indication Insights

The Next-Generation Antibody Therapeutics Market segmentation, based on Target Indication, includes Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma. In 2023, The Acute Myeloid Leukemia category generated the most income. AML represents a significant unmet medical need with limited treatment options, driving the demand for innovative therapies. Next-generation antibody therapeutics offer targeted approaches for AML treatment, including antibody-drug conjugates (ADCs) and bispecific antibodies, which demonstrate promising efficacy and improved outcomes. The high prevalence of AML and the urgency to address this disease further contribute to the dominance of this target indication in the market.

Bladder Cancer Target Indication is experiencing the highest compound annual growth rate (CAGR) in the Next-Generation Antibody Therapeutics Market due to several factors. Bladder cancer represents a significant unmet medical need with limited treatment options, driving the demand for innovative therapies. Next-generation antibody therapeutics, including antibody-drug conjugates (ADCs) and bispecific antibodies, offer promising approaches for bladder cancer treatment, with potential for improved efficacy and reduced toxicity. The growing prevalence of bladder cancer and the urgent need for more effective treatments contribute to the rapid growth of this target indication in the market.

Next-Generation Antibody Therapeutics Type of Therapy Insights

The Next-Generation Antibody Therapeutics Market segmentation, based on Type of Therapy, includes Combination Therapy and Monotherapy. In 2023, the Combination Therapy category generated the most income (60%). Combination Therapy, a type of therapy involving the use of multiple agents or modalities to treat a disease, has captured the largest market share in the Next-Generation Antibody Therapeutics Market due to its synergistic effects and ability to overcome treatment resistance. By combining different types of next-generation antibody therapeutics, such as antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors, with traditional therapies or other novel agents, combination therapy offers enhanced efficacy and improved patient outcomes, driving its dominance in the market.

Monotherapy, a type of therapy involving the use of a single agent or modality to treat a disease, is experiencing the highest compound annual growth rate (CAGR) in the Next-Generation Antibody Therapeutics Market due to several factors. With advancements in antibody engineering and the development of highly potent and selective next-generation antibody therapeutics, monotherapy offers a simplified treatment approach with reduced toxicity and improved patient compliance. Additionally, the expanding pipeline of monoclonal antibodies targeting specific disease pathways drives the growth of monotherapy in the market.

Next-Generation Antibody Therapeutics Route of Administration Insights

The Next-Generation Antibody Therapeutics Market segmentation, based on Route of Administration, includes Intratumoral, Intravenous and Intravesical. In 2023, the Intratumoral category generated the most income due to its direct and targeted delivery of therapeutic agents into the tumor microenvironment. This approach allows for higher local concentrations of antibodies while minimizing systemic exposure and associated toxicities. Intratumoral administration offers advantages such as improved tumor penetration, enhanced efficacy, and reduced treatment-related side effects, making it a preferred route for delivering next-generation antibody therapeutics and driving its dominance in the market.

The Intravenous (IV) route of administration is experiencing the highest compound annual growth rate (CAGR) in the Next-Generation Antibody Therapeutics Market due to its widespread adoption and versatility. IV administration offers advantages such as convenience, rapid systemic distribution, and precise dosing control. Additionally, advancements in drug delivery technologies and the development of long-acting formulations enhance the efficacy and patient experience with IV-administered next-generation antibody therapeutics. The broad applicability and effectiveness of IV administration contribute to its rapid growth in the market.

Figure 1: Next-Generation Antibody Therapeutics Market, by Route of Administration, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Next-Generation Antibody Therapeutics Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Next-Generation Antibody Therapeutics market area will dominate this market high prevalence of chronic diseases. North America has secured the largest market share in the Next-Generation Antibody Therapeutics Market due to several factors. The region boasts a robust healthcare infrastructure, extensive research and development activities, and favorable regulatory policies that support innovation. Additionally, a large patient population, a high prevalence of chronic diseases, and significant investments in biopharmaceutical research contribute to the dominance of North America in the market. Moreover, the presence of key market players and academic institutions further strengthens the region's position in driving advancements and adoption of next-generation antibody therapeutics.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Next-Generation Antibody Therapeutics market accounts for the second-largest market share due to the strong regulatory framework. Europe has secured the second-largest market share in the Next-Generation Antibody Therapeutics Market due to several factors. The region benefits from a well-established healthcare system, strong regulatory framework, and active participation in clinical research and development. Additionally, Europe has a high prevalence of chronic diseases, driving the demand for innovative therapies. Furthermore, strategic collaborations between academic institutions, biopharmaceutical companies, and government bodies foster innovation and contribute to the region's significant presence in the market. Further, the German Next-Generation Antibody Therapeutics market held the largest market share, and the UK Next-Generation Antibody Therapeutics market was the fastest growing market in the European region.

The Asia-Pacific Next-Generation Antibody Therapeutics Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest compound annual growth rate (CAGR) in the Next-Generation Antibody Therapeutics Market due to several factors. These include increasing investments in healthcare infrastructure, rising prevalence of chronic diseases, and expanding research and development activities. Additionally, favorable regulatory reforms, growing healthcare expenditure, and the presence of a large patient population drive market growth in the region. Moreover, strategic partnerships and collaborations with global biopharmaceutical companies contribute to the accelerated adoption of next-generation antibody therapeutics in the Asia Pacific region. Moreover, China’s Next-Generation Antibody Therapeutics market held the largest market share, and the Indian Next-Generation Antibody Therapeutics market was the fastest growing market in the Asia-Pacific region.

Next-Generation Antibody Therapeutics Key Market Players & Competitive Insights

Leading players in the Next-Generation Antibody Therapeutics Market are actively engaged in strategic initiatives to maintain their competitive edge. This includes investments in research and market developments to advance novel antibody formats, such as antibody-drug conjugates (ADCs) and bispecific antibodies, aimed at improving therapeutic efficacy. Additionally, companies are expanding their product pipelines through partnerships, collaborations, and acquisitions to address unmet medical needs across various disease areas. Moreover, efforts to optimize manufacturing processes and ensure regulatory compliance further strengthen their market position and drive innovation.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Next-Generation Antibody Therapeutics industry to benefit clients and increase the market sector. In recent years, the Next-Generation Antibody Therapeutics industry has offered some of the most significant advantages to immunocytokines. Major players in the Next-Generation Antibody Therapeutics market, including Genmab A/S, Seattle Genetics, Inc., Immunomedics, Inc., Daiichi Sankyo Company, Limited, Immunocore Limited, Zymeworks Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Roche Holding AG and Amgen Inc. are attempting to increase market demand by investing in research and development operations.

Genmab A/S, headquartered in Denmark, is a leading biotechnology company specializing in innovative antibody-based therapies for cancer and other diseases. Leveraging proprietary antibody technologies such as DuoBody® and HexaBody®, Genmab develops next-generation antibody therapeutics with enhanced efficacy and reduced toxicity. The company's diverse pipeline includes antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors targeting various cancer types and other indications. Genmab collaborates with strategic partners to accelerate the development and commercialization of its therapies globally. Committed to scientific excellence and innovation, Genmab aims to address unmet medical needs and improve patient outcomes in the rapidly evolving Next-Generation Antibody Therapeutics Market.

Seattle Genetics, Inc., headquartered in the United States, is a leading biotechnology company specializing in the development and commercialization of innovative antibody-based therapies for cancer treatment. The company's flagship product, ADCETRIS® (brentuximab vedotin), is an antibody-drug conjugate (ADC) approved for the treatment of various lymphomas. Seattle Genetics is also advancing a robust pipeline of next-generation ADCs, bispecific antibodies, and other novel antibody-based therapies, leveraging its proprietary antibody-drug conjugate technology and antibody engineering platforms. Through strategic collaborations and partnerships with biopharmaceutical companies worldwide, Seattle Genetics aims to advance the field of oncology and improve patient outcomes by delivering targeted, effective, and well-tolerated therapies in the rapidly evolving Next-Generation Antibody Therapeutics Market.

Key Companies in the Next-Generation Antibody Therapeutics market include

• Genmab A/S


• Seattle Genetics, Inc.


• Immunomedics, Inc.


• Daiichi Sankyo Company, Limited


• Immunocore Limited


• Zymeworks Inc.


• AstraZeneca PLC


• Bristol Myers Squibb Company


• Roche Holding AG


• Amgen Inc.

Next-Generation Antibody Therapeutics Industry Developments

December 2022: Sorrento Therapeutics, Inc. has obtained clearance from the U.S. FDA to commence clinical trials for its next-generation mRNA vaccine (STI-1557) targeting SARS-CoV-2 Omicron variants.

May 2022: Astellas Pharma has announced that the European Commission has granted approval for XTANDI therapy (enzalutamide). XTANDI is the sole oral treatment approved for three types of prostate cancer, comprising non-metastatic, metastatic hormone-sensitive, and metastatic castration-resistant forms.

Next-Generation Antibody Therapeutics Market Segmentation

Next-Generation Antibody Therapeutics Type of Novel Antibody Outlook

• Immunocytokines


• Immunotoxins


• Radioisotope Immunoconjugates

Next-Generation Antibody Therapeutics Target Indication Outlook

• Acute Myeloid Leukemia


• Bladder Cancer


• Diffuse Large B-cell Lymphoma


• Graft-versus-host disease


• Melanoma Prostate Cancer


• Soft-tissue Sarcoma

Next-Generation Antibody Therapeutics Type of Therapy Outlook

• Combination Therapy


• Monotherapy

Next-Generation Antibody Therapeutics Route of Administration Outlook

• Intratumoral


• Intravenous


• Intravesical

Next-Generation Antibody Therapeutics Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America